MAP
SYRE icon

Moody Aldrich Partners’s Spyre Therapeutics SYRE Stock Holding History

Moody Aldrich Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.77M Buy
+42,458
New +$3.1M 0.68% 71

Other funds holding SYRE

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM

Moody Aldrich Partners's SYRE Position: Q2 2026 in Review

Moody Aldrich Partners opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 42,458 shares worth $3.77M. The stake represents 0.68% of the portfolio and ranks #71 among its holdings.

8 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Moody Aldrich Partners held 42,458 shares of Spyre Therapeutics worth $3.77M as of Q2 2026.
  • Spyre Therapeutics was a new Moody Aldrich Partners position in Q2 2026.
  • Spyre Therapeutics made up 0.68% of Moody Aldrich Partners's portfolio in Q2 2026, its #71 holding.
  • 8 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.